Resources
Providing the best advocacy resources for biosimilars.
Whether you are a patient, caregiver, medical professional, payer, policymaker, or you just want to know more about biosimilars, our resources will teach you everything you need to know. Browse through our list below to learn more, and feel free to contact us.
The Biosimilars
Patient Resource Center
The Biosimilars Patient Resource Center is a convenient site for answers to your pressing questions about biosimilar medicines.
Whether you are a current or potential biosimilar or biologics patient, a caregiver, a medical professional, a policymaker, or if you just want to know more about biosimilars, the Biosimilars Patient Resource Center has information you can use.
The Biosimilars Handbook
The Biosimilars Handbook is the premier resource for biosimilar education.
Choose from one of four different tracks below – or check out our additional suggested resources – to learn how biosimilars and interchangeable biologic products can decrease costs and increase access to lifesaving medicines. we’re advocating for right now, and make your voice heard to get these policies across the finish line.
For Patients and Caregivers
FDA – Biosimilars: What Patients Need to Know
Patients Increasingly Rely on Oncology Biosimilar Medicines
Biosimilar Medicines Equal More Accessible Care for America’s Patients
For Medical Professionals
AAM Annual Savings Report – Biosimilars and Bending the Cost Curve
Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption
FDA Biosimilars Approvals
For Payers
AAM Annual Savings Report – Biosimilars and Bending the Cost Curve
Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption
New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption
For Policymakers
The U.S. Generic & Biosimilar Medicines Savings Report
Increase Patient Access to Lower-Cost Biosimilar Medicines
Top Biosimilar Resources
Biosimilars 101
Biosimilars are a safe, effective, and more affordable option for many patients who rely on biologic treatments.
FDA Biosimilars Approvals
Find an up-to-date list of FDA-approved biosimilars and launches.
2023 U.S. Generic and Biosimilar Medicines Savings Report
This annual report is produced by the Institute for Human Data Science (IQVIA), the standard-bearer for measuring data, pharmaceutical use and spending in the United States.
Interchangeability 101 – Biosimilars and Interchangeable Biologics
This white board video from the Biosimilars Council walks through the basics of interchangeability and why biosimilars and interchangeable biologics are more than acceptable replacements for brand biologics.
Other Resources
- All
- Backgrounder
- Biosimilars Bulletin
- Blog
- Council Resource
- Event
- Handbook
- Infographic
- Issue Brief
- Member Spotlight
- Partner Resource
- Policy Recommendation
- Press Release
- Report
- Video
- Whitepapers
November 16, 2023
Blog
Since 2015, the U.S. Food and Drug Administration (FDA) has approved 42 total biosimilars, delivering safe and effective care for… Read more »
August 14, 2023
Report
The Biosimilars Council released a report that tracks the biosimilar insulin market and found that pharmacy benefit managers (PBMs) are... Read more »
July 18, 2023
Biosimilars Bulletin
Friends, Right now, the biosimilars market is at a major inflection point, with momentum building in Congress for new drug... Read more »
July 17, 2023
Blog
Just two weeks ago, the U.S. biosimilars industry entered a new phase when eight biosimilar versions of Humira launched with... Read more »
June 8, 2023
Blog
As policymakers and patients wrestle to contain drug spending, a recent report from the IQVIA Institute for Human Data Science... Read more »
May 16, 2023
Blog
Common sense suggests that if a lower cost product is on the market, then consumers should be able to choose... Read more »
May 4, 2023
Biosimilars Bulletin
To our biosimilars advocates, April was a busy month in the biosimilars realm. Below you’ll find a recap of last... Read more »
April 7, 2023
Biosimilars Bulletin
To our biosimilars advocates, As you will see below, we have made some changes to our monthly bulletin. Our goal... Read more »
March 7, 2023
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton Thank you to everyone who attended Access! 2023 and helped make... Read more »
March 3, 2023
Blog
Event
AAM’s annual conference, Access!, was held February 13-15 in Orlando, Florida, where Biosimilars Council members were joined by leaders from... Read more »
February 21, 2023
Blog
The biosimilars market has reached a new milestone, with the first-ever biosimilar to Humira (adalimumab) recently launching, and as many... Read more »
February 3, 2023
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton This year has begun where last year ended – with high... Read more »
January 10, 2023
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton As we close out 2022 and move into 2023, we are... Read more »
December 2, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton First, thank you to all whose attendance and engagement made GRx+Biosims... Read more »
November 23, 2022
Blog
Event
Earlier this month, AAM and the Biosimilars Council hosted guests in North Bethesda, Maryland for the 2022 GRx+Biosims Conference. This... Read more »
November 3, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton Although we’re entering November, the Biosimilars Council’s efforts to promote biosimilarsare... Read more »
October 25, 2022
Blog
Each year, more biosimilars continue to reach new patients, delivering greater savings to them, taxpayers, and the American healthcare system.... Read more »
October 12, 2022
Blog
As trusted partners for patients, pharmacists have a critical role to play in educating consumers about biosimilar medicines. Biosimilars are... Read more »
October 6, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton September marks the culmination of a significant amount of the Biosimilars... Read more »
October 6, 2022
Blog
Although biosimilars have made great strides in the last year, there remains much work to be done. This point is... Read more »
September 21, 2022
Report
The 2022 U.S. Generic and Biosimilar Savings Report, the annual report from the Association for Accessible Medicines and its Biosimilars... Read more »
September 8, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton Last month, we witnessed the final passage and enactment of the... Read more »
August 19, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton As we write this, the Senate is actively considering the Inflation... Read more »
August 15, 2022
Blog
Since the first biosimilar was approved in the U.S. in 2015, these life savings therapies have provided nearly $13 billion... Read more »
July 26, 2022
Blog
Congress is actively seeking to advance legislation to allow the Medicare program to “negotiate” the prices of brand drugs. However,... Read more »
July 25, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Craig Burton This month, both chambers of Congress made progress in advancing legislation... Read more »
June 28, 2022
Infographic
Biosimilars are safe, effective, FDA-approved medicines used to treat diseases at lower costs than brand-name biologics. To date, biosimilars been used... Read more »
June 8, 2022
Biosimilars Bulletin
A Note from Former Executive Director Christine Simmon As many of you have already heard, May was my last month... Read more »
May 25, 2022
Infographic
In 2010, Congress established the regulatory pathway which ultimately led to the first FDA-approved biosimilar becoming available five years later.... Read more »
May 23, 2022
Blog
On May 23, 2022, the Association for Accessible Medicines and its Biosimilars Council urged the Federal Trade Commission (FTC) to... Read more »
May 20, 2022
Blog
Biosimilar medicines are revolutionary therapeutics that treat patients at a fraction of the cost of brand-name biologics. However, public awareness... Read more »
May 17, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon Biosimilar adoption continues to steadily grow and reach new patients with... Read more »
April 13, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon As we close out Women’s History Month, I would like to... Read more »
April 8, 2022
Blog
Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many PBMs... Read more »
March 23, 2022
Blog
Greg, 37, of Los Angeles, CA., spends most of his time hiking, running and lifting weights, but his greatest passion... Read more »
March 15, 2022
Blog
Eileen, 28, lives in New York City and is pursuing her dream of a career in musical theater. Her stage... Read more »
March 11, 2022
Blog
This year, Congress will consider legislation that codifies performance goals for the review of drug applications by the U.S. Food... Read more »
March 8, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon Happily, members of the Biosimilars Council and AAM were able to... Read more »
February 24, 2022
Blog
Event
February 14-16, AAM and its Biosimilars Council welcomed attendees to Orlando, Florida for Access! 2022, the generics and biosimilars industry’s... Read more »
February 4, 2022
Blog
Last year was full of exciting developments for patients who rely on biosimilars. Here’s a look at what we’re working... Read more »
February 2, 2022
Blog
On February 2 we mark Rheumatoid Arthritis (RA) Awareness Day and shine a light on the roughly 1.5 million Americans... Read more »
January 3, 2022
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon 2021 proved to be an eventful year for the biosimilars community,... Read more »
December 20, 2021
Blog
This week, we learned that employers experienced a 6.3% jump in health benefit costs last year.1Findings such as these, paired with... Read more »
December 6, 2021
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon The second annual Global Biosimilars Week proved a great way to... Read more »
December 3, 2021
Blog
The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines.... Read more »
November 29, 2021
Event
AAM’s 2021 GRx+Biosims conference has officially come to a close, and by all accounts it delivered on its promise to... Read more »
November 3, 2021
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon This month, the Biosimilars Council announced the release of AAM’s 2021... Read more »
October 28, 2021
Blog
Biosimilar medicines are increasingly becoming an essential fixture in health care, reducing prices and increasing patient access. This is especially... Read more »
October 14, 2021
Blog
Since the enactment of the Biologics Price Competition and Innovation Act in 2010, patients with complex disease have been eager... Read more »
October 12, 2021
Report
The 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, proves that the promise of biosimilars is... Read more »
October 7, 2021
Biosimilars Bulletin
A Note from Biosimilars Council Executive Director Christine Simmon September was an exciting month, as we announced the topline findings... Read more »
September 20, 2021
Council Resource
Scroll down to find an updated list of all FDA-approved biosimilars. This list includes information on when biosimilars were approved,... Read more »
September 7, 2021
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry, including policy movement, educational... Read more »
August 6, 2021
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry, including policy movement, educational... Read more »
July 27, 2021
Blog
Since the biosimilars pathway (BPCIA) was established in 2010, 30* biosimilars have been approved. However, due to significant barriers to... Read more »
July 13, 2021
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry, including policy movement, educational... Read more »
July 1, 2021
Blog
Today, a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups sent a letter thanking... Read more »
June 28, 2021
Blog
Biosimilar competition has the potential to provide greater access to important treatments for America’s patients and cost savings for the… Read more »
June 11, 2021
Blog
In recent years, significant attention has been given to the advent of biosimilars, a new class of medicines approved by... Read more »
May 27, 2021
Video
As a single mother, a new grandmother and emerging artist, Akaimi, 44, of San Antonio, TX, has an active and creative... Read more »
May 7, 2021
Blog
Biosimilars were first introduced in the United States about five years ago to treat patients with various medical conditions including... Read more »
April 23, 2021
Press Release
WASHINGTON, D.C. (April 23, 2021) — The Biosimilars Council, representing leading developers of biosimilar medicines, strongly supports the reintroduction, and... Read more »
April 20, 2021
Blog
Access!, AAM’s annual meeting for the generics and biosimilars industry, brings policymakers, influential speakers and industry leaders together to share... Read more »
March 25, 2021
Blog
Since the first biosimilar launched in the U.S. market five years ago, the U.S. Food and Drug Administration (FDA) has... Read more »
February 22, 2021
Whitepapers
The first in a series of papers, this paper examines the challenges to market sustainability for generic and biosimilar medicines... Read more »
February 9, 2021
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
February 4, 2021
Blog
In 2020, cancer claimed the lives of 600,000 Americans. According to the American Cancer Society (ACS CAN), there are approximately... Read more »
January 12, 2021
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
December 22, 2020
Blog
Biosimilar medicines are safe, effective alternative versions of existing brand biologic medicines (known as “reference products”) with scientifically comparable quality, safety... Read more »
December 17, 2020
Video
Diagnosed in her late twenties with incurable stage four non-Hodgkin lymphoma, Helen, now 41 and a wife and mother of... Read more »
December 15, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
November 30, 2020
Event
We’ve just completed this year’s GRx+Biosims 2020, the premier scientific and regulatory event for the U.S. generics and biosimilars industries,... Read more »
November 16, 2020
Blog
Biosimilars are critical to the discussion around health care and its rising costs, as they have the potential to save... Read more »
November 10, 2020
Blog
Today, the U.S. Supreme Court will hear arguments on the constitutionality of the Affordable Care Act (ACA). Although the case... Read more »
November 10, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
October 26, 2020
Blog
The Biologics Price Competition and Innovation Act of 2010 (BPCIA) provides a framework for biosimilars approval, adoption and access in... Read more »
October 22, 2020
Partner Resource
There are approximately 1.7 million new cases of cancer in the United States each year. Patients rely on FDA-approved medications... Read more »
October 13, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
October 12, 2020
Video
In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is... Read more »
October 12, 2020
Blog
Biosimilar developers must combat several obstacles in bringing a product to market, including patent litigations like this, while brand companies... Read more »
October 5, 2020
Blog
Before biologic drugs are ready to be used by patients, scientists and providers spend years developing, researching, and testing them... Read more »
September 28, 2020
Whitepapers
Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (BioDrugs), the International... Read more »
September 28, 2020
Blog
According to a report on biosimilars cost savings in the U.S., biosimilars could lead to over $54 billion in savings... Read more »
September 21, 2020
Blog
Biosimilars are biologic medicines that are highly similar to a previously approved reference biologic currently on the market. But what does that short definition of a biosimilar actually mean?... Read more »
September 1, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
August 3, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
July 23, 2020
Infographic
Patients have an alternative to expensive biologic medicines. Biosimilars are FDA-approved alternatives to reference biologics – much like generic drugs... Read more »
July 22, 2020
Infographic
Biosimilars benefit everyone. Biosimilars are FDA-approved alternatives to reference biologics – much like generic drugs – that provide treatment options... Read more »
July 16, 2020
Whitepapers
Biosimilars in the pharmacy benefit employers driving appropriate use and transparency. Despite the fact that less than 2 percent of... Read more »
July 6, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
June 8, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
June 3, 2020
Whitepapers
Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at AEI, details misconceptions... Read more »
May 4, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
April 7, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
April 6, 2020
Blog
More than 180 million Americans receive health care benefits through their employer, with large employers paying more than 80 percent... Read more »
March 10, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
March 4, 2020
Blog
According to a study released by Pacific Research Institute, biosimilars have the potential to bring significant savings to both state... Read more »
February 27, 2020
Council Resource
“It is absolutely safe for a patient to switch from a biologic to a biosimilar because their qualities are similar.... Read more »
February 11, 2020
Biosimilars Bulletin
Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
January 30, 2020
Blog
2019 was a whirlwind year for biosimilars, highlighted by a record 10 U.S. Food and Drug Administration (FDA) approvals and... Read more »
November 25, 2019
Council Resource
Providing More Patients Greater Access to Lifesaving Medicines Biologics are innovative treatment options for patients affected by debilitating and life-threatening... Read more »
November 21, 2019
Blog
Event
Earlier this month the Association for Accessible Medicines (AAM) and its Biosimilars Council hosted the second annual GRx+Biosims Conference for... Read more »
November 1, 2019
Event
The Association for Accessible Medicines (AAM) and its Biosimilars Council are eager for the start of this year’s GRx+Biosims conference... Read more »
October 24, 2019
Member Spotlight
Sandoz, Inc. Executive Director of Scientific Affairs Hillel Cohen joins us to talk about the future of biosimilars in the... Read more »
October 21, 2019
Infographic
Biologics and biosimilars are both FDA-approved medicines that help patients treat or manage debilitating diseases. All biologic drugs, including biosimilars,... Read more »
October 2, 2019
Blog
When it comes to ensuring medicines — including biosimilars — are safe and effective for patients, the FDA remains the… Read more »
September 9, 2019
Whitepapers
America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access... Read more »
July 23, 2019
In July of 2018, the U.S. Food and Drug Administration (FDA) released the Biosimilars Action Plan (BAP). The plan detailed... Read more »
June 26, 2019
Video
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »
June 25, 2019
Whitepapers
As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars... Read more »
June 25, 2019
Video
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »
June 25, 2019
Member Spotlight
Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. This summer, as part of our commitment to broad stakeholder education about... Read more »
June 24, 2019
Blog
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »
June 24, 2019
Video
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »
July 15, 2019
Member Spotlight
Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. Member Spotlight/Q&A Hillel P. Cohen, Ph.D., Executive Director, Scientific Affairs, Sandoz, Inc., is... Read more »
July 29, 2019
Blog
Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. Written by Hillel P. Cohen Biosimilars are a competitive, effective alternative for... Read more »
May 16, 2019
Council Resource
Insulin has been available to America’s diabetes patients for decades, and millions of patients rely on this medicine every day... Read more »
May 13, 2019
Council Resource
Whitepapers
Insulin has been available to America’s diabetes patients for decades. Millions rely on this medicine every day to control their... Read more »
May 9, 2019
Blog
In a recent for Drug Store News, Chip Davis, President and CEO for the Association of Accessible Medicines, discusses the... Read more »
May 9, 2019
Blog
A recent series in Health Affairs questioned whether competition from biosimilar medicines is a viable path to providing relief from… Read more »
May 3, 2019
Video
Biosimilars are safe, effective medicines for patients that treat some of the most difficult-to-treat conditions such as psoriasis, rheumatoid arthritis... Read more »
April 22, 2019
Blog
The Biologic Patent Transparency Act, introduced in March and sponsored by Senators Susan Collins (R-ME) and Tim Kaine (D-VA), would... Read more »
February 22, 2019
Video
The Biosimilars Council is proud to partner with the International Generic and Biosimilar Medicines Association (IGBA) to launch a new... Read more »
February 22, 2019
Blog
Earlier this month in New Orleans, the Association for Accessible Medicines and its Biosimilars Council hosted our annual Access! Conference. Attendees from... Read more »
February 4, 2019
Blog
Actions by branded companies to undermine proven safe, effective biosimilars hurt patients. U.S. Food & Drug Administration Commissioner Scott Gottlieb... Read more »
May 25, 2022
Infographic
Biosimilars are safe, effective, and competitive alternatives to expensive brand-name biologics that are used to treat serious chronic diseases, like... Read more »
December 10, 2018
Blog
On Friday, December 14, the U.S. Food and Drug Administration (FDA) announced its sixteenth biosimilar approval for biosimilar trastuzumab, a drug used in... Read more »
November 18, 2018
Blog
The American Society of Hematology (ASH) has added to its eLearning platform a new educational course titled “Biosimilars: A New Era of Hematology/Oncology... Read more »
November 15, 2018
Blog
The burden of high prescription medicine costs for America’s patients continues to drive much of the national health care conversation and... Read more »
November 14, 2018
Blog
Scott Knoer, M.S., Pharm.D, serves as Chief Pharmacy Officer for the Cleveland Clinic, one of the largest hospitals nationwide. In... Read more »
November 13, 2018
Blog
A recent Italian study published in Frontiers in Public Health examined the effect of including a pharmacist in the Department of Abdominal... Read more »
October 16, 2018
Blog
Pharmacists are among the most trusted health care professionals in America. Millions of patients rely on their pharmacist for guidance... Read more »
September 25, 2018
Blog
IQVIA, a leading healthcare research company, recently released a new report, “Advancing Biosimilar Sustainability in Europe,” which examines the status of biosimilars... Read more »
September 19, 2018
Video
Ninety-three percent of generic prescription drugs are filled at $20 or less. Watch this video to learn about the benefits... Read more »
September 18, 2018
Partner Resource
Video
What is a biosimilar? How does the European Medicines Agency (EMA) work to ensure that these biological medicines are as... Read more »
September 12, 2018
Event
Friday, September 14, 2018 Noon–1:00 p.m. 1310 Longworth House Office Building Committee on House Administration Hearing Room On August 31,... Read more »
September 11, 2018
Blog
The Biosimilars Council's parent organization, the Association for Accessible Medicines (AAM), is active in promoting education around a variety of... Read more »
September 2, 2018
Blog
Seventeen stakeholder groups representing a variety of healthcare industry’s sent a letter to FDA, urging greater clarity on interchangeability guidance... Read more »
August 31, 2018
Blog
This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
August 28, 2018
Partner Resource
The International Generic and Biosimilars Medicines Association (IGBA) has released an in-depth review of global biosimilar and biologic drug naming... Read more »
August 24, 2018
Partner Resource
This brochure is an original publication of the American Pharmacists Association - a Biosimilars Council partner - and the full... Read more »
August 24, 2018
Partner Resource
This is a replication of an original post (Understanding Biologic and Biosimilar Drugs) on the Cancer Action Network of the... Read more »
August 24, 2018
Partner Resource
This blog post was originally posted on the Cancer Action Network of the American Cancer Society and the full article... Read more »
August 20, 2018
Blog
This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
August 18, 2018
Partner Resource
Click the button below to download the International Generics & Biosimilars Association's (IGBA) 2018 PowerPoint update on facts and figures... Read more »
July 26, 2018
Event
Please join us on Thursday, July 26th at noon for a lunch briefing hosted by the Association for Accessible Medicines (AAM)... Read more »
July 25, 2018
Video
Christine Simmon, Executive Director of AAM's Biosimilars Council, reacts to the recent release of FDA's Biosimilars Action Plan About the... Read more »
July 25, 2018
Report
This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »
July 1, 2018
Infographic
The pharmaceutical industry can be complicated and with new medicines coming to market every day, it can be tough to... Read more »
June 1, 2018
Infographic
Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out... Read more »
May 30, 2018
Report
Whitepapers
America’s patients who suffer from many complex and chronic diseases have promising new treatment options in biologic and specialty medicines.... Read more »
May 25, 2018
Handbook
Reading the Biosimilars Council Handbook is now easier than ever. Click on the image below to browse our interactive Handbook... Read more »
May 10, 2018
Policy Recommendation
Biosimilars have the potential to improve quality of life for patients. If the right policies are put in place to... Read more »
May 4, 2018
Blog
Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion... Read more »
April 30, 2018
Infographic
In the U.S., the FDA is approving more biosimilars and patients are benefitting from these new medicines. Access to these... Read more »
October 30, 2019
Infographic
Since it was created in 2007, the Food & Drug Administration’s (FDA’s) Risk Evaluation and Mitigation Strategies (REMS) has been... Read more »
April 30, 2018
Handbook
In addition to our interactive Handbook, you can also download a PDF copy of the Biosimilars Council's Handbook. Inside this... Read more »
April 30, 2018
Backgrounder
Biosimilars are safe, effective alternative versions of existing biologic medicines (known as “reference products”) with scientifically comparable quality, safety and... Read more »
April 30, 2018
Report
Biologics are medicines extracted from a variety of natural sources—human, animal or microorganism—and include a wide range of products such... Read more »
April 13, 2018
Blog
Science, Data and FDA Support the Safety and Efficacy of Biosimilars for Patients As the biosimilars market begins to expand... Read more »
April 10, 2018
Video
The average annual price of speciality drugs has tripled over the last ten years. Watch this video for information on... Read more »
April 4, 2018
Event
AAM listened to our members and conference attendees and has created the ultimate event for the industry. We combined all... Read more »
April 4, 2018
Event
Thursday, April 19, 2018 – 5-7pm – 601 New Jersey Ave. NW Join The Biosimilars Council and the Association for... Read more »
March 15, 2018
Blog
The Naming of Biosimilar Medicines Worldwide Should Promote Patient Safety and Prescriber Confidence
In response to the growing number of biosimilar approvals and increased acceptance of their safety and efficacy a number of... Read more »
March 13, 2018
Video
The CREATESAct will help increase patient access to generic and biosimilar medicines. This video explainer provides background and information on... Read more »
March 1, 2018
Blog
Today’s healthcare arsenal includes biological products, or biologics, that are used in the treatment, prevention or diagnosis of diseases and... Read more »
February 15, 2018
Blog
2017 was a watershed year for patients seeking affordable alternatives to expensive biologic medicines . The number of FDA-approved biosimilars more... Read more »
February 7, 2018
Blog
Since their first use in the 1980s, biologic medicines have grown to become an indispensable tool in modern medicine. Advancements... Read more »
December 19, 2017
Blog
For anyone following the nascent biosimilars market in the U.S., 2017 has been a busy year: the Centers for Medicare... Read more »
December 1, 2017
Blog
Biosimilars hold great promise for patients seeking access to more affordable versions of critical medicines, but also for a health care system facing unsustainable, increasing costs. One of the most immediate challenges to biosimilars uptake in the United State sis the lack of […]
November 20, 2017
Issue Brief
It is the Biosimilars Council’s position that Congress established pass-through status to foster innovation and to remove financial barriers to... Read more »
November 10, 2017
Issue Brief
Biosimilar medicines are safe, effective and affordable versions of costly brand biologics for the treatment of cancer, rheumatoid arthritis and... Read more »
October 4, 2017
Blog
In the fast-paced world of health care, the role of the patient continues to evolve from passive to active. One of the most pressing issues patients face is the cost of their medications, which can serve as a significant barrier to access, especially for expensive brand-name biologic medicines[…]
September 1, 2017
Blog
Event
Join us as we examine the promise of biosimilars in the United States and discuss how best to ensure patient... Read more »
July 25, 2017
Blog
This week, Avalere Health published new research that found 81% of health insurers are covering at least one of the... Read more »
July 6, 2017
Report
This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »
June 27, 2017
Blog
On June 7th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Update on Biosimilars” at the Newseum in Washington, D.C. The third in a series of Atlantic biosimilars briefings underwritten by The Biosimilars Council […]
June 6, 2017
Blog
Biosimilars not only have the unique ability to provide patients with much-needed access to lower-cost complex therapies, but also offer the potential for billions in patient, insurer and health system savings. But there are barriers […]
May 31, 2017
Backgrounder
Informative fact sheet listing the multitude of benefits of biosimilar medications. Includes useful statistics about the state of the industry.... Read more »
May 25, 2017
Blog
Working in coordination with The Atlantic, an award-winning publication that covers politics, business, and technology, The Biosimilars Council will continue its efforts to educate consumers about biosimilars by bringing together key stakeholders to debate the state and future of biosimilars […]
May 8, 2017
Blog
The country has undergone a great deal of change from December to today – but one thing that has not changed is that Americans want action to bring down the price of prescription drugs. A recent Kaiser Health Tracking Poll showed that over 60% of Americans believe lowering the cost of […]
March 28, 2017
Blog
On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by The Biosimilars Council, more than 100 influencers from across the […]
March 1, 2017
Event
Underwritten by The Biosimilars Council The Atlantic gathered key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States. How does the Food and Drug Administration implement[…]
March 1, 2017
Event
Join The Atlantic as we gather key stakeholders to examine the future for biosimilars domestically and abroad. What impact will... Read more »
Stay Informed About The Latest Issues.
Subscribe to the monthly Biosimilars Bulletin.